Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunesis Pharmaceuticals has received a new US patent no. 7,989,468 from the US Patent and Trademark Office (USPTO) for vosaroxin as a treatment for leukemia.
Subscribe to our email newsletter
The new patent covers the methods of using vosaroxin at clinically relevant dose ranges and schedules for leukemia treatment.
Sunesis is now recruiting patients for Valor Phase 3 double-blind, randomized, placebo-controlled trial to evaluate vosaroxin in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.
Sunesis Pharma CEO Dan Swisher said the ‘468 patent adds another important facet to their global intellectual property estate for vosaroxin, providing significant coverage for uses of vosaroxin in the treatment of leukemia including the dose and schedule under evaluation in the pivotal, Phase 3 Valor trial.
"To supplement our granted patents, we have filed patent applications in territories around the world with claims covering additional vosaroxin formulations, combination uses, dosing, manufacturing processes and composition of matter claims, which may provide patent terms to 2030 when granted," Swisher said.